Spots Global Cancer Trial Database for autologous transplantation
Every month we try and update this database with for autologous transplantation cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Long-Term Follow-up Study for Non-Hodgkin's Lymphoma Patients Who Received Study Treatment (Plerixafor or Placebo) in the AMD3100-3101 Study (NCT00103610). | NCT00741325 | Non-Hodgkin's L... Autologous Tran... | granulocyte col... plerixafor Placebo | - | Sanofi | |
| Ponatinib With Chemotherapy for Young Adults Ph Positive Acute Lymphoblastic Leukemia | NCT02776605 | ALL | Prednisone Vincristine Daunorubicin Prednisone Ponatinib Mercaptopurine Methotrexate VP-16 ARA-C: TIT Ponatinib Autologous tran... Allo transplant... | 18 Years - 55 Years | PETHEMA Foundation | |
| Long-Term Follow-up Study for Multiple Myeloma Patients Who Received Study Treatment (Plerixafor or Placebo) in the AMD3100-3102 Study (NCT00103662). | NCT00741780 | Multiple Myelom... Autologous Tran... | Placebo plerixafor granulocyte col... | - | Sanofi | |
| Study of the Best Timing for Plerixafor in Autologous Hematopoietic Stem Cell Collection | NCT01042717 | Multiple Myelom... Non-Hodgkins Ly... | Plerixafor | 18 Years - 75 Years | Shi, Patricia, M.D. | |
| R-MegaCHOP-ESHAP-BEAM in Patients With High-Risk Aggressive B-Cell Lymphomas | NCT00558220 | Diffuse Large B... Primary Mediast... Follicular Lymp... | immunotherapy Induction treat... Induction treat... Induction treat... Consolidation t... Consolidation t... | 18 Years - 65 Years | Czech Lymphoma Study Group | |
| Ponatinib With Chemotherapy for Young Adults Ph Positive Acute Lymphoblastic Leukemia | NCT02776605 | ALL | Prednisone Vincristine Daunorubicin Prednisone Ponatinib Mercaptopurine Methotrexate VP-16 ARA-C: TIT Ponatinib Autologous tran... Allo transplant... | 18 Years - 55 Years | PETHEMA Foundation | |
| Safety, Tolerability, PK/PD of FE 203799 in Adults With Lymphomas | NCT03417765 | Lymphoma, Non-H... Lymphoma, Hodgk... | FE 203799 | 18 Years - 70 Years | VectivBio AG | |
| Pethema Multiple Myeloma 2000 | NCT00560053 | Multiple Myelom... | Alternating che... Autologous Tran... Maintenance Second transpla... ALOGENIC MINI T... | - 69 Years | PETHEMA Foundation | |
| Melphalan 200 mg/m2 Versus Melphalan 100 mg/m2 in Newly Diagnosed Myeloma Patients | NCT00950768 | Multiple Myelom... Diagnosis | Autologous tran... | 18 Years - 65 Years | Azienda Ospedaliera San Giovanni Battista | |
| Autologous Stem Cell Transplant (ASCT) With Intravenous Busulfan and Melphalan as Conditioning Regimen | NCT00804947 | Multiple Myelom... | Intravenous bus... | 18 Years - 70 Years | Fundacion Para La Investigacion Hospital La Fe | |
| Impact of DMSO Concentrations on Hematopoietic Recovery After Autologous HSC Transplantation. | NCT02452099 | Multiple Myelom... Lymphomas Leukemias | Cryopreservatio... Cryopreservatio... Cryopreservatio... | 18 Years - | Maria Sklodowska-Curie National Research Institute of Oncology | |
| Treatment of Newly Diagnosed Elderly Patients With Multiple Myeloma | NCT00367185 | Multiple Myelom... | Thalidomide | 65 Years - 75 Years | University Hospital, Lille | |
| Long-Term Follow-up Study for Non-Hodgkin's Lymphoma Patients Who Received Study Treatment (Plerixafor or Placebo) in the AMD3100-3101 Study (NCT00103610). | NCT00741325 | Non-Hodgkin's L... Autologous Tran... | granulocyte col... plerixafor Placebo | - | Sanofi | |
| Exploratory Study on POL6326 in Stem Cell Mobilization | NCT01105403 | Multiple Myelom... | POL6326 | 18 Years - 70 Years | Polyphor Ltd. | |
| Clinical And Economic Impact Of Upfront Plerixafor In Autologous Transplantation | NCT01339572 | Non-Hodgkin's L... Multiple Myelom... | Plerixafor Filgrastim | 18 Years - | University of Florida | |
| IFM 99-02 Thalidomide in Myeloma | NCT00222053 | Multiple Myelom... | Thalidomide Biphosphonates | 18 Years - 65 Years | University Hospital, Toulouse | |
| Long-Term Follow-up Study for Multiple Myeloma Patients Who Received Study Treatment (Plerixafor or Placebo) in the AMD3100-3102 Study (NCT00103662). | NCT00741780 | Multiple Myelom... Autologous Tran... | Placebo plerixafor granulocyte col... | - | Sanofi | |
| Rituximab Maintenance After Autologous Transplantation | NCT01103388 | Non-Hodgkin's L... | Rituximab | - | M.D. Anderson Cancer Center | |
| Treatment of Relapsed Promyelocytic Leukemia With Arsenic Trioxide (ATO) | NCT00504764 | Acute Promyeloc... | Arsenic Trioxid... Autologous Tran... Allogenic Trans... ATRA | 18 Years - | PETHEMA Foundation | |
| Study of the Best Timing for Plerixafor in Autologous Hematopoietic Stem Cell Collection | NCT01042717 | Multiple Myelom... Non-Hodgkins Ly... | Plerixafor | 18 Years - 75 Years | Shi, Patricia, M.D. | |
| Treatment of Newly Diagnosed Elderly Patients With Multiple Myeloma | NCT00367185 | Multiple Myelom... | Thalidomide | 65 Years - 75 Years | University Hospital, Lille | |
| AMD3100 (Plerixafor) in Multiple Myeloma (MM) or Non-Hodgkin's Lymphoma (NHL) Patients Predicted to be Unable to Mobilize With G-CSF Alone | NCT00395967 | Multiple Myelom... Lymphoma, Non-H... | G-CSF plus pler... | 18 Years - 75 Years | Sanofi | |
| Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With AML Leukemia | NCT00049517 | Leukemia | sargramostim busulfan cyclophosphamid... cytarabine gemtuzumab ozog... Daunorubicin Autologous HCT Allogeneic HCT | 16 Years - 60 Years | Eastern Cooperative Oncology Group | |
| Risk-adapted Therapy for Adult Acute Myeloid Leukemia. | NCT01716793 | Leukemia, Myelo... | Ara-C Autologous tran... Allogeneic HLA-... CD34+ selection | 18 Years - 60 Years | Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias | |
| Long-Term Follow Up Study for AMD3100 Patients | NCT00476294 | Myeloma | Telephone Quest... | 18 Years - 78 Years | M.D. Anderson Cancer Center | |
| Pharmacokinetic Study of Propylene Glycol-Free Melphalan HCl for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation | NCT02669615 | Multiple Myelom... | Melphalan HCl f... | 18 Years - | Medical College of Wisconsin | |
| A Phase I Study of WT1 Peptides to Induce Anti-Leukemia Immune Responses Following Transplantation | NCT00672152 | Acute Myelogeno... Chronic Myeloge... Acute Lymphobla... Myelodysplastic... B Cell Malignan... | WT1 derived pep... | 18 Years - | Duke University | |
| AMD3100 (Plerixafor) Given to NHL and MM Patients to Increase the Number of PBSCs When Given a Mobilizing Regimen of G-CSF | NCT00396266 | Multiple Myelom... Lymphoma, Non-H... | G-CSF Plus Pler... | 18 Years - 70 Years | Sanofi |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
